GlaxoSmithKline Intellectual Property Development Limited
发明人:
Andy FEDORIW,Sarah GERHART,Ryan G. KRUGER,Jenny LARAIO,Helai MOHAMMAD,Shane W. OBRIEN,Jacob RUBIN
申请号：
US16465630
公开号：
US20190365710A1
申请日:
2017.11.30
申请国别(地区):
US
年份:
2019
代理人:
摘要：
This invention relates to methods of treating cancer in a subject in need thereof, e.g., in a human in need thereof, comprising determining the level of 5-Methylthioadenosine phosphorylase (MTAP) polynucleotide or polypeptide or the presence or absence of a mutation in MTAP in a sample from the human, and administering to the human an effective amount of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor if the level of the MTAP polynucleotide or polypeptide is decreased relative to a reference or if a mutation in MTAP polynucleotide or polypeptide is present, thereby treating the cancer in the human.
